Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Apr 27;14(2):209.
doi: 10.1186/ar3791.

Role of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathies

William Coley  1 , Sree Rayavarapu, Kanneboyina Nagaraju
Affiliations
Review

Role of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathies

William Coley et al. Arthritis Res Ther. .

Abstract

Idiopathic inflammatory myopathies (IIMs) comprise a group of autoimmune diseases that are characterized by symmetrical skeletal muscle weakness and muscle inflammation with no known cause. Like other autoimmune diseases, IIMs are treated with either glucocorticoids or immunosuppressive drugs. However, many patients with an IIM are frequently resistant to immunosuppressive treatments, and there is compelling evidence to indicate that not only adaptive immune but also several non-immune mechanisms play a role in the pathogenesis of these disorders. Here, we focus on some of the evidence related to pathologic mechanisms, such as the innate immune response, endoplasmic reticulum stress, non-immune consequences of MHC class I overexpression, metabolic disturbances, and hypoxia. These mechanisms may explain how IIM-related pathologic processes can continue even in the face of immunosuppressive therapies. These data indicate that therapeutic strategies in IIMs should be directed at both immune and non-immune mechanisms of muscle damage.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relationship between the possible pathologic mechanisms leading to idiopathic inflammatory myopathies.ER, endoplasmic reticulum; MHC, major histocompatibility complex; TLR, Toll-like receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve. 2003;27:407–425. doi: 10.1002/mus.10313. - DOI - PubMed
    1. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, Sato T, Kiuchi T, Ohashi Y. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995;22:668–674. - PubMed
    1. Miller F, Rider L, Plotz P, Oddis C, Isenberg D. Diagnostic criteria for polymyositis and dermatomyositis. Lancet. 2003;362:1762–1763. doi: 10.1016/S0140-6736(03)14862-3. - DOI - PubMed
    1. Santmyire-Rosenberger B, Dugan EM. Skin involvement in dermatomyositis. Curr Opin Rheumatol. 2003;15:714–722. doi: 10.1097/00002281-200311000-00006. - DOI - PubMed
    1. Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am. 2002;28:833–857. doi: 10.1016/S0889-857X(02)00024-8. - DOI - PubMed

Publication types